Novo Nordisk A/S Common Stock (NVO)

You won't need a huge amount of cash to invest in these great pharma stocks.

September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025. These new duties, targeting sectors from pharmaceuticals to heavy trucks and home furnishings, signal a deepening

To gain an edge, this is what you need to know today.

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.

These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.

There's an opportunity to get in on the weight-loss drug craze at a reasonable price.

The latest data from the company's oral weight loss drug is bullish for the stock.

The pharmaceutical leader is gradually laying the groundwork for a strong rebound.

Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug.

As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating inflation, divergent central bank policies, and persistent geopolitical tensions define a landscape where careful stock selection is paramount. Against this backdrop, five

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a niche segment has exploded into a multi-billion-dollar arena, driven by highly effective new medications, primarily GLP-1 receptor agonists, that are

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on the burgeoning market for weight-loss and diabetes drugs, driven by its groundbreaking GLP-1 agonists. In stark contrast, Johnson & Johnson (NYSE:

Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity and diabetes treatment markets. The pharmaceutical giant's impressive financial performance was largely propelled by the skyrocketing demand for its incretin-based

These stocks share several common denominators, including attractive valuations.

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

Novo Nordisk (NVO) is a top GARP stock with strong growth, exceptional profitability, and a reasonable valuation, making it a compelling investment opportunity.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

A lot has gone wrong for the drugmaker recently.

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of

Eli Lilly (NYSE: LLY) is poised to further solidify its dominance in the burgeoning diabetes and weight loss markets following a cascade of overwhelmingly positive clinical trial results for its blockbuster injectable Mounjaro (tirzepatide) and its highly anticipated oral GLP-1 receptor agonist, Orforglipron. The findings, which demonstrate Mounjaro's efficacy in